[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@kjerath Kunal Jerath
Kunal Jerath posts on X about $axsm, $nvct, $mnpr, future the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: undefined #
- X Week XXXXX -XX%
- X Month XXXXXX +67%
- X Months XXXXXX +95%
- X Year XXXXXX +204%
Mentions: undefined #
- X Week XX -XX%
- X Month XX +40%
- X Months XXX +171%
- X Year XXX +224%
Followers: XXX #
- X Week XXX +0.66%
- X Month XXX +0.49%
- X Months XXX +12%
- X Year XXX +20%
CreatorRank: undefined #
Social Influence
Social category influence finance XX%
Social topic influence $axsm 50%, $nvct #1, $mnpr #1, future 16.67%, ipo 8.33%, stocks 8.33%, crypto 8.33%, core 8.33%, $qure 8.33%, $imrx XXXX%
Top accounts mentioned or mentioned by @lpessa7654
Top assets mentioned Axsome Therapeutics, Inc (AXSM) uniQure N.V. (QURE)
Top Social Posts
Top posts by engagements in the last XX hours
"I'm lucky that I never sold $AXSM since the IPO. And now because of that I can feel ok with stocks that are taking time to work out like $NVCT (feels like Waiting for Godot) or the recent pullback in crypto. Thank you $AXSM Now every $XX it goes up I will sell 1-2%"
X Link 2025-11-06T18:28Z XXX followers, 1134 engagements
"Great close on $AXSM today. Sold X% of my core holding at the close. The position is too concentrated. Love the future of this company"
X Link 2025-11-21T21:33Z XXX followers, XXX engagements
"They have been correct scientifically on $IMRX and $QURE although they have been wrong on how the stock would perform in the short run in each case. Similarly they have been wrong on $NVCT in the short run call for NXP-800 to be a clearing event for shorts to be stuck"
X Link 2025-11-22T13:37Z XXX followers, XXX engagements
"I remember when $AXSM and $MNPR first came public. Their first drug failed and the company didn't get any credit for anything in their pipeline. That's the way biotech works. Once your first drug doesn't succeed the market goes in to "wait and see" mode. It's often a good time"
X Link 2025-12-03T13:59Z XXX followers, XXX engagements
"to invest because valuations are disconnected from fundamentals. This is a similar case currently for $NVCT. NXP-800 may succeed in the future but it didn't succeed with ovarian cancer (3 different trials were done). Now it's like $AXSM and $MNPR - no one is paying up for the"
X Link 2025-12-03T13:59Z XXX followers, XXX engagements
"for data since NXP-800 failed because if NXP-900 works it doesn't matter if they buy at $X or $XX or $XX - it's still a home run. But at $X the potential for $NVCT is similar to $AXSM and $MNPR in terms of returns. Now management must deliver"
X Link 2025-12-03T13:59Z XXX followers, XXX engagements
"Years ago I gifted shares of $AXSM to my kids. This year (and last) I gifted them $NVCT shares. Hoping it will be as transformative for them as $AXSM investment turned out to be"
X Link 2025-12-08T15:46Z XXX followers, XXX engagements